Optimized Synthesis of Pioglitazone Drug Nanocarriers

A study published in the journal International Journal of Molecular Sciences proposes a plausible modification of the most crucial formulating variables for producing PGZ-packed PLGA nanoparticles using nanoprecipitation or single emulsification-solvent evaporation techniques.

Optimized Synthesis of Pioglitazone Drug Nanocarriers

Study: Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method. Image Credit: Crevis/Shutterstock.com

Using Pioglitazone to Control Progression of Atherosclerosis

Atherosclerosis is a severe disorder characterized by increasing infection and gradually calcifying ulcers in the artery wall's intima and interior components as a result of the development of plaques. Moreover, type-2 diabetes worsens atherosclerotic ulcers.

Although the link between antidiabetic medicines and the advancement of atherosclerosis remains unknown, Pioglitazone (PGZ), a commonly administered diabetes drug, has been shown to delay the growth of atherosclerosis.

PGZ is a tiny, somewhat hydrophobic molecule that is often utilized in treating or progressing the management of type-2 diabetes. Nevertheless, owing to its poor and pH-dependent solubility, short half-life in plasma because of fast hepatic metabolism, dose-based systemic adverse reactions, and nonspecific drug administration, PGZ's applicability is severely restricted.

To address this issue, appropriate nanocarriers, such as nanoparticles (NPs), may increase PGZ therapeutic effectiveness while reducing adverse effects.

Benefits of Nanoscale Drug Delivery Systems

Nanoparticles (NPs) are nanoscale systems in which either an artificial or biological polymer wall defines a cavity containing the active material (nanocapsules) or the active material is evenly scattered (nanospheres).

Generally, the nanoparticles-based drug carrier strategy is based on the ability to transport active materials primarily to the sick tissue and with greater intracellular absorption than free medicines. This results in not only a strong medicinal defense against systemic problems but also higher preservation of healthy cells.

Why PLGA-based Nanoparticles are the Way Forward?

Latest studies on nanoparticles predicated on poly(lactic-co-glycolic acid) (PLGA) as drug carriers are based on the field's growing knowledge of PLGA characteristics and chemical reconfiguration methods, which are used to optimize NP drug packing and releasing aspects.

The kinetics of polymer-based nanoparticles' breakdown are influenced by multiple variables, including polymer–water interactions, crystalline nature of the polymer, temperature, the existence of heteroatomic or hydrophilic groups, polymeric chain expansion and the employment of instigators in synthesizing, the concentration of polymer, pH, and salt levels.

PLGA is typically broken down by hydrolysis, which converts oligomers into bio-friendly monomers. PLGA is a material authorized by food and drug regulators and with its minimal toxicity, good cytocompatibility and biodegradability, and customizable structural characteristics, is especially suitable for drug administration.

The Two Synthesis Approaches

The optimal preparation strategies for enclosing hydrophobic pharmaceuticals were recommended to be single emulsification-solvent evaporation or nanoprecipitation. In the single emulsification-solvent evaporation method, the NPs are generated in two phases.

First, a polymeric solution is made in a water-insoluble organic solvent with high volatility. The colloid mixture of micelles is then created by introducing an emulsifying aqueous solution and forcefully combining the two phases with an ultrasonic mixer; the NP suspension is then produced by evaporating out the solvent.

The nanoprecipitation approach, in contrast, is centered around dumping a high volatility organic solvent miscible in water and containing the polymer into an aqueous phase. Slow stirring produces a colloidal NPs suspension. As a result, unlike the other method, the generated suspension may be stabilized by a moderate amphiphilic chemical such as PVA. This approach is often straightforward and quick, yielding particles with low polydispersity index (PDI) values.

Important Takeaways of the Study

The purpose of this study was to describe pioglitazone encasing utilizing PLGA NPs. After experimenting with two different approaches to nanomaterial production, the researchers determined that the nanoprecipitation technique produced superior outcomes with respect to size, PDI, encasing efficiency, drug loading, price, and processing time.

Only in the stability experiment did the NPs formed by single emulsion–solvent evaporation outperform those generated by nanoprecipitation, since those generated by nanoprecipitation tended to agglomerate throughout the freeze and thaw cycles.

This tendency is associated with a less negative zeta potential for NPs produced by the nanoprecipitation approach. Even after aggregation, their average diameter remained within the acceptable range.

There is no overall ideal synthesis process, but the architecture of the nanoparticles must be modified based on the chemical-physical properties of the encased medicine.

Looking Ahead

The robustness of the produced NPs acquired by nanoprecipitation may be increased down the line, for example, by adjusting the cryo-preservative solution or employing PEGylated PLGA in part to lower the agglomeration propensity without significantly affecting the NPs' properties.

Reference

Todaro, B., Moscardini, A., & Luin, S. (2022). Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method. International Journal of Molecular Sciences, 23(5). Available at: https://doi.org/10.3390/ijms23052522

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Shaheer Rehan

Written by

Shaheer Rehan

Shaheer is a graduate of Aerospace Engineering from the Institute of Space Technology, Islamabad. He has carried out research on a wide range of subjects including Aerospace Instruments and Sensors, Computational Dynamics, Aerospace Structures and Materials, Optimization Techniques, Robotics, and Clean Energy. He has been working as a freelance consultant in Aerospace Engineering for the past year. Technical Writing has always been a strong suit of Shaheer's. He has excelled at whatever he has attempted, from winning accolades on the international stage in match competitions to winning local writing competitions. Shaheer loves cars. From following Formula 1 and reading up on automotive journalism to racing in go-karts himself, his life revolves around cars. He is passionate about his sports and makes sure to always spare time for them. Squash, football, cricket, tennis, and racing are the hobbies he loves to spend his time in.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Rehan, Shaheer. (2022, February 28). Optimized Synthesis of Pioglitazone Drug Nanocarriers. AZoNano. Retrieved on July 02, 2022 from https://www.azonano.com/news.aspx?newsID=38756.

  • MLA

    Rehan, Shaheer. "Optimized Synthesis of Pioglitazone Drug Nanocarriers". AZoNano. 02 July 2022. <https://www.azonano.com/news.aspx?newsID=38756>.

  • Chicago

    Rehan, Shaheer. "Optimized Synthesis of Pioglitazone Drug Nanocarriers". AZoNano. https://www.azonano.com/news.aspx?newsID=38756. (accessed July 02, 2022).

  • Harvard

    Rehan, Shaheer. 2022. Optimized Synthesis of Pioglitazone Drug Nanocarriers. AZoNano, viewed 02 July 2022, https://www.azonano.com/news.aspx?newsID=38756.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit